650 related articles for article (PubMed ID: 26432382)
1. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.
Springuel L; Renauld JC; Knoops L
Haematologica; 2015 Oct; 100(10):1240-53. PubMed ID: 26432382
[TBL] [Abstract][Full Text] [Related]
2. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
3. Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Mughal TI; Girnius S; Rosen ST; Kumar S; Wiestner A; Abdel-Wahab O; Kiladjian JJ; Wilson WH; Van Etten RA
Leuk Lymphoma; 2014 Sep; 55(9):1968-79. PubMed ID: 24206094
[TBL] [Abstract][Full Text] [Related]
4. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
6. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
7. Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer.
Rizwi FA; Abubakar M; Puppala ER; Goyal A; Bhadrawamy CV; Naidu VGM; Roshan S; Tazneem B; Almalki WH; Subramaniyan V; Rawat S; Gupta G
J Environ Pathol Toxicol Oncol; 2023; 42(4):15-29. PubMed ID: 37522565
[TBL] [Abstract][Full Text] [Related]
8. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
9. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
10. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
Yang X; Tang Z; Zhang P; Zhang L
Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity and resistance of JAK2 inhibitors to myeloproliferative neoplasms.
Bhagwat N; Levine RL; Koppikar P
Int J Hematol; 2013 Jun; 97(6):695-702. PubMed ID: 23670175
[TBL] [Abstract][Full Text] [Related]
12. The JAK-STAT pathway: a therapeutic target in hematological malignancies.
Ferrajoli A; Faderl S; Ravandi F; Estrov Z
Curr Cancer Drug Targets; 2006 Dec; 6(8):671-9. PubMed ID: 17168672
[TBL] [Abstract][Full Text] [Related]
13. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
14. Jak/Stat pathway in Waldenström's macroglobulinemia.
Hodge LS; Ansell SM
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):112-4. PubMed ID: 21454207
[TBL] [Abstract][Full Text] [Related]
15. Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity.
Bailetti AA; Negrón-Piñeiro LJ; Dhruva V; Harsh S; Lu S; Bosula A; Bach EA
Dis Model Mech; 2019 May; 12(5):. PubMed ID: 31072879
[TBL] [Abstract][Full Text] [Related]
16. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
17. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
[TBL] [Abstract][Full Text] [Related]
18. Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.
Bharadwaj U; Kasembeli MM; Robinson P; Tweardy DJ
Pharmacol Rev; 2020 Apr; 72(2):486-526. PubMed ID: 32198236
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
20. Tools and methods for studying the Drosophila JAK/STAT pathway.
Chen Q; Giedt M; Tang L; Harrison DA
Methods; 2014 Jun; 68(1):160-72. PubMed ID: 24685392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
